Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS • Currently up 7.51 (+3.58%) in today's trading session

3 members of Congress have disclosed 6 trades in Jazz Pharmaceuticals plc (JAZZ) via STOCK Act filings. The most recent disclosure was a sale by Thomas R. Suozzi on 26 September 2022. The most active traders have been Thomas R. Suozzi (4), Bill Flores (1), and Jim Cooper (1). Aggregate disclosed activity totals roughly $56.5K in purchases and $8K in sales (midpoint estimates from bracketed disclosure amounts).

Jazz Pharmaceuticals plc is currently trading at $217.16, positioned at 64% of its 52-week range ($128.80 – $266.38).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$217.16
24h Change
+7.51 (+3.58%)
52 Week Range
$128.80–$266.38
View on NASDAQ

Jazz Pharmaceuticals plc Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for JAZZ

Select to highlight on chart
5 transactions
Compliance: 33%
Thomas R. Suozzi26 Sept 20223 May 2023SaleStock$1,001 - $15,000N/A
Thomas R. Suozzi19 Oct 20215 Nov 2021PurchaseStock$1,001 - $15,000N/A
Thomas R. Suozzi19 Oct 202119 Dec 2022PurchaseStock$1,001 - $15,000N/A
Thomas R. Suozzi19 Oct 202113 Aug 2022PurchaseStock$1,001 - $15,000N/A
Bill Flores15 Jul 201912 Aug 2019PurchaseStock$15,001 - $50,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$14.1B

Volume

290.91K

Beta

0.32

P/E Ratio

8.10

Fundamentals

EPS

$26.82

Div. Yield

-

Open

$212.19

Day Range

$212.19 – $217.52

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
IE
CEO
Renee D. Gala
IPO Date
2007-06-01

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...

Earnings

Next Report

Q3 2026

4 Nov

EPS Est.

$6.30

Rev. Est.

$1.2B

Days Until

20

Recent Quarters

Q2 20263 Aug
EPS$5.71
Miss 7.6%
Q1 20265 May
EPS$6.34
Beat 36.6%
Q4 202524 Feb
EPS$6.64
Beat 1.8%
Q3 20255 Nov
EPS$8.13
Beat 36.6%
Q2 20255 Aug
EPS$-8.25
Miss 34.8%
Q1 20256 May
EPS$1.68
Miss 62.8%
Q4 202425 Feb
EPS$6.60
Beat 13.2%
Q3 20246 Nov
EPS$6.61
Beat 20.8%
Q2 202431 Jul
EPS$5.30
Beat 13.3%
Q1 20241 May
EPS$2.68
Miss 35.3%
Q4 202328 Feb
EPS$5.02
Miss 4.6%
Q3 20238 Nov
EPS$4.84
Miss 1.2%
Q2 20239 Aug
EPS$4.51
Beat 1.1%
Q1 202310 May
EPS$3.95
Miss 7.3%
Q4 20221 Mar
EPS$-0.07
Miss 113.7%
Q3 20229 Nov
EPS$5.17
Beat 9.5%
Q2 20223 Aug
EPS$4.30
Beat 2.4%
Q1 20224 May
EPS$3.73
Miss 0.5%
Q4 20211 Mar
EPS$4.21
Beat 13.5%
Q3 20219 Nov
EPS$4.20
Beat 28.4%
Q2 20213 Aug
EPS$3.90
Beat 9.9%
Q1 20214 May
EPS$3.92
Beat 6.2%
Q4 202023 Feb
EPS$4.00
Miss 2.4%
Q3 20202 Nov
EPS$4.31
Beat 7.0%
Q2 20204 Aug
EPS$3.71
Beat 9.8%
Q1 20205 May
EPS$0.45
Miss 31.8%
Q4 201925 Feb
EPS$4.42
Beat 6.3%
Q3 20195 Nov
EPS$4.10
Beat 14.2%
Q2 20196 Aug
EPS$4.05
Beat 13.4%
Q1 20197 May
EPS$3.67
Beat 16.1%
Q4 201826 Feb
EPS$3.64
Beat 22.1%
Q3 20186 Nov
EPS$3.58
Beat 7.5%
Q2 20187 Aug
EPS$3.49
Beat 8.4%
Q1 20188 May
EPS$2.98
Beat 8.0%
Q4 201727 Feb
EPS$2.95
Miss 1.0%
Q3 20177 Nov
EPS$3.22
Beat 11.4%
Q2 20178 Aug
EPS$2.56
Miss 5.5%
Q1 20179 May
EPS$2.31
Miss 1.7%
Q4 201628 Feb
EPS$2.71
Beat 2.6%
Q3 20168 Nov
EPS$2.57
Miss 1.5%
Q2 20169 Aug
EPS$2.63
Miss 7.7%
Q1 201610 May
EPS$2.26
Miss 3.0%
Q4 201523 Feb
EPS$2.60
Beat 0.4%
Q3 20159 Nov
EPS$1.39
Miss 45.5%
Q2 20155 Aug
EPS$2.41
Beat 0.0%
Q1 20157 May
EPS$1.99
Miss 6.6%
Q4 201424 Feb
EPS$2.44
Beat 4.3%
Q3 20144 Nov
EPS$2.33
Beat 6.4%
Q2 20145 Aug
EPS$2.05
Beat 6.2%
Q1 20148 May
EPS$1.61
Miss 13.4%
Q4 201325 Feb
EPS$1.72
Miss 4.4%
Q3 20135 Nov
EPS$1.78
Beat 7.2%
Q2 20136 Aug
EPS$1.43
Miss 5.9%
Q1 20137 May
EPS$1.37
Beat 5.4%
Q4 201226 Feb
EPS$1.53
Beat 4.8%
Q3 20128 Nov
EPS$1.29
Miss 3.0%
Q2 20127 Aug
EPS$1.09
Beat 3.8%
Q1 20128 May
EPS$0.91
Beat 8.3%
Q4 201127 Feb
EPS$1.17
Beat 7.3%
Q3 20111 Nov
EPS$0.94
Beat 0.0%
Q2 201128 Jul
EPS$0.82
Beat 3.8%
Q1 20113 May
EPS$0.59
Beat 3.5%
Q4 20107 Mar
EPS$0.63
Beat 5.0%
Q3 20104 Nov
EPS$0.41
Beat 20.6%
Q2 201010 Aug
EPS$0.28
Beat 100.0%
Q1 20105 May
EPS$0.18
Beat 0.0%
Q4 20093 Mar
EPS$0.17
Beat 142.9%
Q3 20095 Nov
EPS$-0.05
Beat 64.3%
Q2 200914 Aug
EPS$0.07
Q2 200911 Aug
EPS$0.07
Beat 121.9%
Q4 200826 Mar
EPS$-2.04
Miss 90.7%
Q3 200813 Nov
EPS$-1.07
Beat 17.1%
Q2 20087 Aug
EPS$-2.17
Miss 21.9%
Q1 200813 May
EPS$-1.97
Miss 25.5%
Q4 200713 Feb
EPS$-1.69
Beat 7.1%
Q3 20076 Nov
EPS$-0.82
Beat 41.4%
Q2 200710 Aug
EPS$-2.96
Q2 20079 Aug
EPS$-1.38
Beat 18.3%
Q3 200631 Dec
EPS$-0.92
Q2 200630 Sept
EPS$-0.92
Q1 200630 Jun
EPS$-0.92
Q4 200531 Mar
EPS$-1.66
Q3 200531 Dec
EPS$-1.58
Q2 200530 Sept
EPS$-1.58
Q1 200530 Jun
EPS$-1.58
Q4 200431 Mar
EPS$-1.58

4 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

50
$1269.54+60.80 (+5.03%)
Healthcare
Held by same politician
Same sector: Healthcare
+1 more reason
1 politician
View Stock

MS

Morgan Stanley

47
$179.93-1.58 (-0.87%)
Financial Services
2 politicians both hold this
Significant holdings value
2 politicians
View Stock

VLO

Valero Energy Corporation

44
$448.57-11.21 (-2.44%)
Energy
2 politicians both hold this
2 politicians
View Stock

Frequently Asked Questions about JAZZ

Which members of Congress have traded JAZZ?
3 members of Congress have disclosed 6 trades in Jazz Pharmaceuticals plc (JAZZ) under the STOCK Act. The most active traders are Thomas R. Suozzi, Bill Flores, and Jim Cooper.
When was JAZZ most recently disclosed by Congress?
The most recent JAZZ disclosure was a sale by Thomas R. Suozzi on 26 September 2022.
What is the total disclosed congressional trading volume for JAZZ?
Members of Congress have disclosed approximately $56.5K in JAZZ purchases and $8K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in JAZZ?
This JAZZ page updates as soon as new STOCK Act disclosures are filed for Jazz Pharmaceuticals plc. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.